MARKET

FGEN

FGEN

FibroGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.42
-0.81
-4.00%
After Hours: 19.11 -0.31 -1.60% 18:04 05/10 EDT
OPEN
20.09
PREV CLOSE
20.23
HIGH
20.17
LOW
19.26
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
57.21
52 WEEK LOW
18.12
MARKET CAP
1.79B
P/E (TTM)
-9.1063
1D
5D
1M
3M
1Y
5Y
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
Zacks.com · 4h ago
10-Q: FIBROGEN INC
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 5h ago
FibroGen EPS beats by $0.09, misses on revenue
FibroGen (FGEN): Q1 GAAP EPS of -$0.78 beats by $0.09.Revenue of $38.43M (+57.5% Y/Y) misses by $3.41M.Press Release
Seekingalpha · 5h ago
FibroGen Q1 EPS $(0.78) Beats $(0.87) Estimate, Sales $38.40M Miss $41.79M Estimate
FibroGen (NASDAQ:FGEN) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.87) by 10.34 percent. This is a 12.36 percent increase over losses of $(0.89) per share from the same
Benzinga · 6h ago
FibroGen Reports First Quarter 2021 Financial Results
Roxadustat net product revenue in China of $15.4 million, on a US GAAP basis Total roxadustat net sales in China of $43.5 million1 by FibroGen and the...
GlobeNewswire · 6h ago
FibroGen, Inc. to Host Earnings Call
May 10, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / May 10, 2021 / FibroGen, Inc. (NASDAQ:FGEN) will be discussing their earnings results in...
ACCESSWIRE · 7h ago
FibroGen Narrows Q1 Loss as Revenue Rises
MT Newswires · 9h ago
-- Earnings Flash (FGEN) FIBROGEN Posts Q1 Loss $-0.78, vs. Street Est of $-0.91
MT Newswires · 9h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FGEN. Analyze the recent business situations of FibroGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FGEN stock price target is 40.57 with a high estimate of 56.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 319
Institutional Holdings: 75.55M
% Owned: 82.06%
Shares Outstanding: 92.07M
TypeInstitutionsShares
Increased
71
5.51M
New
28
1.12M
Decreased
74
3.12M
Sold Out
25
423.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Director
James Schoeneck
Chief Executive Officer/Director
Enrique Conterno
Chief Financial Officer
Pat Cotroneo
Other
K. Peony Yu
Senior Vice President
Christine Chung
Senior Vice President
Elias Kouchakji
Other
Percy Carter
Other
Mark Eisner
Other
Thane Wettig
Lead Director/Independent Director
Thomas Kearns
Director
Aoife Brennan
Director
Benjamin Cravatt
Independent Director
Suzanne Blaug
Independent Director
Jeffrey Edwards
Independent Director
Jeffrey Henderson
Independent Director
Maykin Ho
Independent Director
Kalevi Kurkijarvi
Independent Director
Gerald Lema
Independent Director
Rory Riggs
Independent Director
Toshinari Tamura
No Data
About FGEN
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).

Webull offers kinds of FibroGen Inc stock information, including NASDAQ:FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.